BioLineRx Ltd. (BLRX)
| Market Cap | 9.50M -40.9% |
| Revenue (ttm) | 1.39M -91.9% |
| Net Income | -6.99M |
| EPS | -1.50 |
| Shares Out | 2.62B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,792 |
| Open | 1.950 |
| Previous Close | 2.020 |
| Day's Range | 1.940 - 1.991 |
| 52-Week Range | 1.940 - 3.950 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | 22.00 (+1,005.53%) |
| Est. Earnings | Nov 23, 2026 |
About BLRX
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic... [Read more]
Financial Performance
In 2025, BioLineRx's revenue was $1.18 million, a decrease of -95.92% compared to the previous year's $28.94 million. Losses were -$1.18 million, -87.26% less than in 2024.
Financial StatementsAnalyst Summary
The average 12-month stock price target for BLRX is $22.0, which is an increase of 1,005.53% from the latest price.
News
BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand th...
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
TEL AVIV, Israel and OSLO, Norway, Oct. 8, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and ...
BioLineRx files to sell 2.02M American Depositary Shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.02M American Depositary Shares. The company is not selling any shares…
BioLineRx Registration statement: Registration filing
BioLineRx filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Releases Q2 2026 Financial Results
BioLineRx Ltd. The post BioLineRx Releases Q2 2026 Financial Results first appeared on Alphastreet .
BioLineRx Earnings Call Transcript: Q2 2026
GLIX1 advanced in clinical and preclinical studies, showing efficacy in glioblastoma and synergy with PARP inhibitors in ovarian cancer. Q2 2026 saw steady royalty revenue, increased R&D expenses, and a net loss of $4.3 million, with cash runway into 2027.
BioLineRx Earnings release: Q2 2026
BioLineRx released its Q2 2026 earnings on August 31, 2026, summarizing the period's financial results.
BioLineRx reports Q2 EPS 0c vs 0c last year
Reports Q2 revenue $294,000 vs $304,000 last year. As of June 30, 2026, the Company had cash, cash equivalents, and short-term bank deposits of $13.1M. “During the second quarter and…
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September - - Announced new data showing GLIX1 achieved potent antitum...
BioLineRx prices 1.35M ADSs at $2.78 in registered direct offering
BioLineRx (BLRX) announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the company’s American Depositary Shares at a purchase price of…
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies i...
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx (BLRX) Earnings Preview: GLIX1 Progress Meets a Tighter Cash Runway
Current Operating Story and Business Drivers BioLineRx Ltd. (BLRX) heads into its next update as a much narrower company than... The post BioLineRx (BLRX) Earnings Preview: GLIX1 Progress Meets a Tigh...
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and...
BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor
BioLineRx (BLRX) announced new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft model of ovarian cancer. Today’s results represent a “comp...
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individual...
BioLineRx (BLRX) Q1 2026 Earnings Transcript
BioLineRx (BLRX) Q1 2026 Earnings Transcript
BioLineRx Earnings Call Transcript: Q1 2026
GLIX1 entered phase I/IIa trials for GBM, showing strong preclinical results and broad market potential. APHEXDA sales and royalties grew significantly, while R&D expenses rose due to pipeline expansion. Cash reserves are sufficient into 2027.
BioLineRx Earnings release: Q1 2026
BioLineRx released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
BioLineRx reports Q1 EPS 0c vs. (0c) last year
Reports Q1 revenue $0.5M vs.$0.3M last year. “Since our last quarterly update, we achieved a significant milestone for our company and for the GLIX1 development program with the dosing of…
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-...
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
TEL AVIV, Israel and OSLO, Norway, May 22, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and ...
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx and Hemispherian report new GLIX1 anti-tumor effect in GBM
BioLineRx (BLRX) and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, announced highly encouraging new preclinical data that further support the recentl...